The lack of a genetic mammalian model in which to study DUX4-mediated muscle pathology, and to test therapeutic interventions targeting DUX4, is currently a major roadblock in understanding of and developing treatments for FSHD. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.